Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 500
Summary
- Conditions
- Pregnancy Following IVF With PGS/PGD
- Type
- Observational
- Design
- Time Perspective: Cross-Sectional
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks gestation. Subjects will received $200 reimbursement for providing this blood sample. The collected samples will be used to help develop non-invasive prenatal diagnostic testing using Natera's Parental Suppor...
Eligible subjects will sign a consent form and have blood drawn at approximately 8-17 weeks gestation. Subjects will received $200 reimbursement for providing this blood sample. The collected samples will be used to help develop non-invasive prenatal diagnostic testing using Natera's Parental Support technology which is already commercialized for genetic diagnosis of in-vitro embryos. In this study, the technology will be tested for it's ability to analyze fetal-specific pieces of DNA isolated from the mother's blood. No results of the maternal blood testing will be reported to the subject or to their physicians.
Tracking Information
- NCT #
- NCT01546324
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Matthew Rabinowitz, PhD CEO, Natera, Inc
Get Well Soon